Cargando…

New first-line treatment strategies for advanced lung squamous cell carcinoma

Detalles Bibliográficos
Autores principales:	Cai, Xiuyu, Yu, Hui, Cai, Yanyu, Zhang, Bei, Zhou, Yixin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225139/ https://www.ncbi.nlm.nih.gov/pubmed/32420085 http://dx.doi.org/10.21037/tlcr.2020.03.14

Ejemplares similares

Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer
por: Zhou, Yixin, et al.
Publicado: (2020)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma
por: Fei, Kailun, et al.
Publicado: (2020)

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)

CheckMate 227 trial has not checked the immune-strategy in first-line setting in advanced non-small cell lung cancer
por: Remon, Jordi, et al.
Publicado: (2020)

KEYNOTE-407: new hope for the treatment of lung squamous cell carcinoma
por: Zhao, Xinmin, et al.
Publicado: (2020)

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
por: Chen, Hao, et al.
Publicado: (2023)

Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer
por: Yamaguchi, Teppei, et al.
Publicado: (2019)

First-line immune-chemotherapy combination for squamous NSCLC is already a reality
por: Hendriks, Lizza E. L., et al.
Publicado: (2020)

First-line management of advanced non-small-cell lung cancer: can we do better?
por: Chouaïd, Christos, et al.
Publicado: (2023)

Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line
por: Roth, Gael S., et al.
Publicado: (2020)

The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung
por: Ichiki, Yoshinobu, et al.
Publicado: (2020)

Nimotuzumab combined with chemotherapy as first‐line treatment for advanced lung squamous cell carcinoma
por: Si, Xiaoyan, et al.
Publicado: (2018)

New potential targeted strategies in small cell lung cancer
por: de Toro, María, et al.
Publicado: (2023)

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer
por: Travert, Camille, et al.
Publicado: (2019)

First-line immune checkpoint inhibitors for patients with metastatic urothelial carcinoma treated in routine clinical practice
por: Naito, Renato, et al.
Publicado: (2020)

Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma
por: Qiu, Hai‐Bo
Publicado: (2020)

First-line cytotoxic chemotherapy regimen for non-small cell lung cancer in the elderly population: plus ça change
por: Dy, Grace K., et al.
Publicado: (2020)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block
por: Hockenhull, Kimberley, et al.
Publicado: (2021)

In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancer
por: Bindal, Poorva, et al.
Publicado: (2020)

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
por: Hida, Toyoaki, et al.
Publicado: (2020)

Advancing Germany’s new global health strategy
por: Stratil, Jan M, et al.
Publicado: (2018)

Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer
por: Nakai, Hidekatsu, et al.
Publicado: (2023)

The KEYNOTE-189 trial as a new paradigm making cure a reality for metastatic non-squamous non-small cell lung cancer
por: Wang, Yanye, et al.
Publicado: (2020)

Anti-PDL1 effect in squamous non-small cell lung cancer
por: Rahouma, Mohamed, et al.
Publicado: (2020)

Lung ultrasound must be the first-line image technique in COVID-19 patients
por: Torres-Macho, Juan, et al.
Publicado: (2023)

PARP inhibitors, use early in the first-line maintenance therapy setting but with caution
por: Giudice, Elena, et al.
Publicado: (2023)

Recent Advances in Oral Squamous Cell Carcinoma
por: Caruntu, Ana, et al.
Publicado: (2022)

Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma
por: Wang, Yunchao, et al.
Publicado: (2022)

Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer
por: Giuliani, Jacopo, et al.
Publicado: (2021)

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
por: Viteri, Santiago, et al.
Publicado: (2020)

The KEY for chemo-immunotherapy combination: taking NOTEs from squamous cell lung cancer
por: Reale, Maria Lucia, et al.
Publicado: (2020)

Efficacy of radiotherapy in combination with first-line immunotherapy and chemotherapy for advanced lung squamous cell carcinoma: a propensity score analysis
por: Qin, Jian, et al.
Publicado: (2023)

Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma
por: Jiang, Tao, et al.
Publicado: (2021)

BRD4 regulates the induction and maintenance of cancer stem cells in squamous cell carcinoma
por: Hamad, Mawieh, et al.
Publicado: (2022)

Utility of miRNA biomarkers for detection of early head and neck squamous cell carcinoma
por: Ershadifar, Soroush, et al.
Publicado: (2023)

Lung cancer in India: Current status and promising strategies
por: Parikh, P. M., et al.
Publicado: (2016)

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
por: Yellala, Amulya, et al.
Publicado: (2020)

Immunotherapy in non-small cell lung cancer: advancements and challenges
por: Zhou, Fei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gqjum4n1u087lcjs8hl2kjv558